ClinicalTrials.gg
RecruitingNCT06507579Updated Aug 18, 2026

Hydra Registry - UK

An observational study in Aortic Valve Stenosis, sponsored by Sahajanand Medical Technologies Limited. Recruiting at 4 sites in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Sahajanand Medical Technologies Limited · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
250
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Aortic Valve Stenosis with a site in United Kingdom — 20 open to participants now, 34 under way, 2 of them phase 3. Aortic Valve Stenosis · United Kingdom.

Planned enrollment
32nd of 61
250 · median 252
Started
2024
with 8 others
Observational
61 of 107
9 open now
Primary completion
2027-07
later than 21 of 33 live
Registered
100th of 107
by date

Among the 107 studies in Aortic Valve Stenosis with a site in United Kingdom, this one is the 32nd largest by planned enrollment of the 61 observational ones that give a count, is one of 9 that started in 2024, is one of 61 observational ones, reaches primary completion later than 21 of the 33 other live ones, and was the 100th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

20 of the 107 studies in Aortic Valve Stenosis with a site in United Kingdom are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Aortic Valve Stenosis with a site in United Kingdom, or all of them as a file.
02

Study summary

The study will evaluate the efficacy and safety of transcatheter aortic valve implantation (TAVI) using the Hydra transcatheter aortic heart valve (THV) series, in patients with severe aortic stenosis up to 1-year after the procedure. This will include an evaluation of the preservation of coronary access post implant by attempting to selectively engage both the right and left coronary arteries through standardised angiographic views.

The study will also examine the utility of 72 hours of post discharge remote ambulatory continuous electrocardiogram (ECG) monitoring using the novel Checkpoint Cardio System where it is clinically appropriate.

Read the detailed description

This is a prospective, observational, multi-centre study. The aim of this study is to collect clinical, procedural, and follow-up data in order to evaluate the efficacy and safety of the Hydra THV series (Vascular Innovations Co. Ltd., Nonthaburi, Thailand).

Additionally, the study will conduct the following evaluation:

  1. The remote ambulatory cardiac monitoring (rACM) using the Checkpoint Cardio System, consisting of 72 hours of continuous electrocardiogram (ECG) monitoring, will be evaluated post hospital discharge where it is clinically appropriate.
  2. Coronary access will be evaluated immediately post-TAVI by attempting to selectively engage both the right and left coronary arteries through standardised angiographic views. This will be done in a sub-set of patients who are either known to have coronary artery disease, did not have coronary angiogram prior to TAVI or where it is felt to be clinically appropriate for other reasons post implant.

Following discharge, clinical follow-ups are scheduled at 45 days (±14 days), and 1-year (±30 days).

03

Conditions studied

  • Aortic Valve Stenosis

Keywords

  • Aortic Valve Stenosis, TAVI, Hydra
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with severe aortic valve stenosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with severe aortic stenosis eligible for transfemoral TAVI procedure as per local Heart Team evaluation
  2. Full understanding and willing to provide to study enrolment
  3. Age ≥ 18 years

Exclusion criteria

Exclusion Criteria:

  1. to TAVI (e.g., anatomically phenotypes, intracardiac mass, thrombus, vegetation, endocarditis)
  2. Refusal to provide to study enrolment
  3. Patients with severe aorta or peripheral artery disease precluding transfemoral approach of TAVI
  4. Patients with significant calcification of the aortic annulus and in the Left Ventricular Outflow Tract (LVOT), or/and excess calcium within each cusp, or those who are deemed unsuitable for the Hydra THV series based on the clinical judgment of the Investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
250 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Severe aortic valve stenosis

    Hydra transcatheter aortic valve (THV) series

    Device: Hydra transcatheter aortic valve (THV) series

Interventions

  • DeviceHydra transcatheter aortic valve (THV) series

    The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.

06

What researchers measure

Primary outcomes

  1. Primary safety endpoint

    Early safety as defined by VARC-3 as composite of: * Freedom from all-cause mortality; * Freedom from all stroke; * Freedom from VARC 3 type 3-4 bleeding; * Freedom from major vascular, access-related, or cardiac structural complication; * Freedom from acute kidney injury stage 3 or 4; * Freedom from moderate or severe aortic regurgitation; * Freedom from new permanent pacemaker due to procedure-related conduction abnormalities; * Freedom from surgery or intervention related to the device.

    Time frame: 45 days

  2. Primary performance endpoint

    Device success as defined by VARC-3 as composite of: * Technical success; * Freedom from mortality; * Freedom from surgery or intervention related to the device or to a major vascular or access related or cardiac structural complication; * Intended performance of the valve (mean gradient \<20mmHg, peak velocity \<3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation).

    Time frame: 45 days

Secondary outcomes

  1. Technical success

    As per VARC-3 defined criteria

    Time frame: Immediately after the procedure

  2. Cardiovascular mortality

    Time frame: 45 days, and 1-year

  3. All-cause mortality

    Time frame: 45 days, and 1-year

  4. All stroke

    Time frame: 45 days, and 1-year

  5. Disabling stroke

    Time frame: 45 days, and 1-year

  6. Myocardial infarction

    Time frame: 45 days, and 1-year

  7. Major vascular complication

    Time frame: 45 days

  8. Acute kidney injury

    Time frame: 45 days

  9. New permanent pacemaker implantation due to procedure related conduction abnormalities

    Time frame: 45 days, and 1-year

  10. New-onset atrial fibrillation

    Time frame: 45 days, and 1-year

  11. Coronary artery obstruction requiring intervention

    Time frame: 45 days, and 1-year

  12. Re-hospitalization for procedure- or valve-related causes

    Time frame: 45 days, and 1-year

  13. Mean aortic valve gradient

    Time frame: 45 days, and 1-year

  14. Effective Orifice Area (EOA)

    Time frame: 45 days, and 1-year

  15. Paravalvular leak

    Time frame: 45 days, and 1-year

  16. New York Heart Association (NYHA) functional class

    Time frame: 45 days, and 1-year

  17. Change in quality-of-life score assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12)

    Assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12)

    Time frame: 45 days, and 1-year

  18. Bioprosthetic Valve Failure (BVF), defined as valve-related mortality or aortic valve re-operation/re-intervention, or stage 3 haemodynamic severe structural valve deterioration

    Time frame: 45 days, and 1-year

  19. Bioprosthetic valve dysfunction (BVD), defined as structural valve deterioration, non-structural valve deterioration, clinical valve thrombosis, infective endocarditis

    Time frame: 45 days, and 1-year

  20. Stroke or peripheral embolism (presumably valve-related, after ruling out other non-valve aetiologies)

    Time frame: 45 days, and 1-year

  21. VARC-3 Type 3-4 bleeding secondary to or exacerbated by antiplatelet or anticoagulant agents used specifically for valve-related concerns (e.g., clinically apparent leaflet thrombosis)

    Time frame: 45 days, and 1-year

  22. Significant arrhythmias on rACM that would potentially lead to permanent pacemaker implantation (PPMI)

    Time frame: 72 hours post hospital discharge

  23. Ability to selectively engage and obtain diagnostic epicardial coronary angiography images from the right and left coronary ostia

    Time frame: Immediately post-TAVI

07

Study locations

2 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 36 months after the start.

Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 36 months is close to that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 18, 2024
StartActual
Jul 11, 2024
Primary completionEst.
Jul 11, 2027
CompletionEst.
Aug 1, 2027
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06507579
Lead sponsor
Sahajanand Medical Technologies Limited
Collaborators
Psephos Biomedica
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Jul 11, 2024
Primary completion
Jul 11, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Aug 18, 2026

Study contacts

Dr. Javaid Iqbal, MRCP, PhD
Contact
J.Iqbal@sheffield.ac.uk
7788438471
Dr. Javaid Iqbal, MRCP, PhD
principal investigator · Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion